Navigation Links
Study Shows Lantus(R) Helped People Living with Type 2 Diabetes Reach the ADA's Recommended Target for Blood Sugar Control
Date:6/7/2008

New data presented at the ADA's Annual Scientific Sessions demonstrated the value of beginning insulin promptly when glycemic targets are not achieved

with diet, exercise and oral medications alone

SAN FRANCISCO, June 7 /PRNewswire-FirstCall/ -- Results from a new study presented at the American Diabetes Association's (ADA) 68th Annual Scientific Sessions reinforce the importance of promptly initiating insulin treatment when patients with type 2 diabetes are unable to achieve recommended glycemic targets with diet, exercise and oral diabetes medications alone. In the TULIP (Testing the Usefulness of Lantus(R) when Initiated Promptly in patients with type 2 diabetes) clinical study, 66 percent of patients who began treatment with the long-acting, basal insulin Lantus(R) (insulin glargine [rDNA origin] injection) achieved A1C <7%, the ADA's recommended target for glycemic control, while only 38 percent of patients from the lifestyle management arm were able to achieve the recommended target levels.

In an effort to help guide treatment decisions, the ADA and European Association for the Study of Diabetes (EASD) developed a Consensus Algorithm for Type 2 Diabetes that calls for healthcare providers and diabetes patients to initiate insulin therapy when A1C <7% is not achieved with oral medications and lifestyle management alone. However, physicians typically wait for A1C to approach 9% before adding insulin. In general, every percentage point drop in A1C blood test results (e.g., from 8.0% to 7.0%) reduces the risk of microvascular complications (eye, kidney, and nerve diseases) by 40%.

The most common side effect of any insulin, including Lantus(R), is hypoglycemia, which may be serious. In the Lantus(R) arm of the TULIP trial, there were 4.2 +/- 6.6 (p<0.0001) cases of symptomatic, 0.7 +/- 2.1 (p=0.0011) cases of nocturnal and 0.04 +/- 0.35 (p=0.147) cases of severe hypoglycemia events reported per patient year. However, no pa
'/>"/>

SOURCE sanofi-aventis
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. The Largest Ever Study of Diabetes Shows Intensive Glucose Control Reduces Serious Complications
2. Leading Academic Institutions Collaborate on 800-Patient Study of Effectiveness of Cryoablation for Men With Recurrent Prostate Cancer
3. Study Supports Possible Use of Leukine(R) as a Potential Adjuvant Therapy for High-Risk Melanoma Patients
4. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
5. Newly Published Study Shows OPKOs siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
6. Ion Mobility Diagnostic Test from Quest Diagnostics is First to Provide Direct Physical Measurement of Lipoprotein Particles, Cardiovascular Disease Indicators, Study Finds
7. Wound Management Technologies, Inc. Announces Evidence Based Study
8. CellCyte Genetics Corporation Selects Washington University School of Medicine to Perform Study on CellCytes Glycoprotein Products in Heart Attack Disease Model
9. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
10. Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
11. Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/6/2008)...IPPENHAM, England, October 7 /PRNewswire-FirstCall... Index: 4565) and Vectura,Group plc ("Vectura"; LS...evaluating the efficacy, safety and tolerability o...uropean Respiratory Society (ERS) in Berlin,Germa...bromide), a novel,inhaled long-acting muscarinic a...
(Date:10/6/2008)... 6 /PRNewswire-USNewswire/ -- "A return to the use...opment is without scientific,justification," accor...rnatives to Laboratory Animals (ATLA). "An Assessm...earch" concludes that vaccine responses in,chimpan...d that claims of,chimpanzees, critical role and im...
(Date:10/6/2008)...video clips feature children, parents discussing c...ETHESDA, Md., Oct. 6 /PRNewswire-USNewswire/ -- Fr...rch in children saves lives and improves their,hea...al Institutes of,Health (NIH), "Children and Clini...es.nhlbi.nih.gov ), offers parents and health,care...
(Date:10/6/2008)...m Phase 3b Studies with Durezol Dosed Prior to Sur...Therapeutics, Inc., a,privately held ophthalmic-fo...hat Durezol(TM) (difluprednate ophthalmic emulsion...ich was approved by the U.S. Food and,Drug Adminis...icosteroid,indicated for the treatment of inflamma...
Breaking Medicine Technology:NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 2NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 3NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 4NVA237 Phase II Results Presented at the European Respiratory Society Annual Meeting Show Promising Efficacy and Tolerability With Potentially Faster Onset Than Tiotropium 5Research Attributes Lack of HIV/AIDS Vaccine to Use of Chimpanzees 2Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 2Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 3Photos: NIH Launches New Web Site for Parents on Medical Research Studies for Children 4Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 2Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 3Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 4Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain 5Innovative Uses of Technology to Improve Health for Poor and Vulnerable People to be Explored at Rockefeller Foundation Conference 20872 1Innovative Uses of Technology to Improve Health for Poor and Vulnerable People to be Explored at Rockefeller Foundation Conference 20872 2Innovative Uses of Technology to Improve Health for Poor and Vulnerable People to be Explored at Rockefeller Foundation Conference 20872 3Innovative Uses of Technology to Improve Health for Poor and Vulnerable People to be Explored at Rockefeller Foundation Conference 20872 4Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation 5739 1Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation 5739 2Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation 5739 3Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation 5739 4Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation 5739 5OHSU Cancer Institute finds that drug stimulated immune system in prostate cancer 20869 1OHSU Cancer Institute finds that drug stimulated immune system in prostate cancer 20869 2OHSU Cancer Institute finds that drug stimulated immune system in prostate cancer 20869 3Latest Advances in Infection Prevention and Control to be Presented in Denver CO at Worlds Largest Annual Infection Prevention Conference June 15 19 20866 1
...rimary Endpoint of Improvement in Overall,Survival...rstCall/ --,Allos Therapeutics, Inc. today announc...otal Phase 3 study of Efaproxyn ,(efaproxiral) plu...th brain metastases originating from breast cancer... of demonstrating a,statistically significant impr...
...2007 /PRNewswire-FirstCall/ -- Anadys,Pharmaceutic...to,the discovery, development and commercializatio...s and cancer, announced today that it,has nominate...s an,orally-administered direct antiviral for the ...tion. , "We have identified a small-molecule, non-...
Other Medicine Technology:Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 2Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 3Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 4Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 5Allos Therapeutics Reports Results for Phase 3 Enrich Study of,Efaproxyn in Women With Brain Metastases Originating From Breast,Cancer 6Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule,Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for,Clinical Development in Chronic Hepatitis C Virus Infection 2Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule,Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for,Clinical Development in Chronic Hepatitis C Virus Infection 3Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule,Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for,Clinical Development in Chronic Hepatitis C Virus Infection 4
(Date:10/6/2008)...de effects can affect length of stay, study says ,...Simple changes to hospital procedures can signific...e on opiates to relieve pain, a new study reveals.... 14 U.S. children,s hospitals, documented a 67 per...in relievers under these new procedures. , The...
(Date:10/6/2008)...ased resource designed to engage and educate viewe...ns including Health Savings Accounts (HSAs), Healt...ing Accounts (FSAs), has partnered with sister com...ices in concert with its existing direct-to-broker... MINNEAPOLIS (Business Wire EON) Oc...
(Date:10/6/2008)...eukemia Victim Ernie Davis, Is, Spokesperson for T...ght(R) Walk, WHI...s, a 1960s,football hero who was the first African...t of the new film from Universal Pictures, The Exp...ercame seemingly insurmountable,obstacles to becom...
(Date:10/6/2008)... Today, PARI Pharma GmbH will,unveil a prototype C...le,dose ampoules to control medication used in the...-dose ampoule that is required to operate the,nebu...ets an unmet need by,reducing the risk of using th...ying filling procedures, improving dose uniformity...
Breaking Medicine News(10 mins):Health News:Hospital Fixes Cut Opiate Errors in Kids 2Health News: LearnCDHC Bridges Education Gap on Consumer Directed Healthcare : Interactive Web resource engages and educates consumers about consumer-directed healthcare 2Health News: LearnCDHC Bridges Education Gap on Consumer Directed Healthcare : Interactive Web resource engages and educates consumers about consumer-directed healthcare 3Health News:Release of Universal Film The Express Draws Attention to Tragedy of Lives Cut Short by Blood Cancer 2Health News:PARI Pharma Unveils Closed System Using eFlow Technology at Medical Plastics Conference 2
...omen had about a 20 percent lower chance of develo... new research bolsters the theory that the female ...al cancer. Dr. Carlo La Vecchia, who led the s...uspected that estrogen in the pill could protect a...
...re is poorly controlled. Drugs and lifestyle modif...rtension) yet these measures are not being taken b...he Baylor School of Medicine, Houston, Texas, doct...00 adults over 25 and found that 27 per cent had h...
...anization for Scientific Research (NWO) discovered...tance to disease if they took extra zinc in additi..., zinc was largely ignored due to the difficulty i...Scientists now know that zinc deficiency leads to ...
...er these days, wonder premature memory loss is no... too much work causing lack of concentration, memo...erations in memory and neurotransmitters are found...nson's disease and Alzheimer's disease. // The fun...
Other Medicine News:
The IntraStent DoubleStrut Biliary Stent represents a completely new direction in stent design. The combination of parallel struts and unique cell geometry provide unparalleled performance.
The Smart Check Syphilis Device is a qualitative membrane device based immunoassay for the detection of TP (Treponema Pallidum) antibodies in whole blood/serum/plasma. For professional in vitro diagn
Bio-Quant, Inc. OneStep hCG InstaTest is an immunochromatographic assay designed for qualitative determination of human chorionic gonadotropin (hCG) in urine for early detection of pregnancy.
OneStep Midstream Urine hCG Pregnancy InstaTest is a test kit for the determination of hCG(Human Chorionic Gonadotropin) in urine specimens. This test kit is used to obtain a visual, qualitative resu
Medicine Products: